A late-stage biopharmaceutical company dedicated to metabolic and chronic liver diseases is developing an in vitro diagnostic (IVD) test for NASH at-risk patients. The test integrates four independent biomarkers – miR-34a-5p, A2M, YKL-40, and HbA1c. The output is a 0-10 score with threshold values, identifying patients with low risk or high risk of developing NASH.

The main objective of this study is to evaluate the physiological stability of these biomarkers between the fed and fasting state in patients with the target condition (NAFLD) over a 30-day period.

Discover how our team of experts helped this biopharmaceutical company to reach its goals

In immuno-oncology (I/O), meeting budget and timeline expectations in the journey from translational research to commercialization is a challenge. You need expert, integrated central laboratory and diagnostic solutions delivered by top scientists who will help you assess needs and generate early insights that optimize your protocol.

What else should you look for in a clinical laboratory partner? Along with access to a sizable patient database, impeccable performance across the globe, and I/O experience, three main testing capabilities are mandatory for success in this field: immunohistochemistry, flow cytometry, and next-generation sequencing.

The challenges in immuno-oncology (I/O) drug development require deep scientific insights, generation and analysis of complex biological data, new state-of-the art technologies and both logistical & operational support across continents. The goal of immuno-oncology drug developers is to turn precision medicine into action, bringing life-changing therapies to patients.

In this webinar originally held on October 4 our experts discuss the use of Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and Flow Cytometry (FCM) within immuno-oncology, and how they can offer the comprehensive insights required for I/O clinical trials.

Speakers

• Jérôme Sallette, PhD, CSO Cerba Research
• Shu Jen Chen, PhD, CSO ACT Genomics
• Sofie Vandevyver, PhD, Head of Business Operations & Marketing Cerba Research
• George Wei, PhD, Vice President R&D ACT Genomics
• Renaud Burrer, PhD, Head of Histopathology Cerba Research
• Nithianandan Selliah, PhD, Global Head Flow Cytometry Cerba Research

On November 16, 2021 Cerba Research and Akoya Biosciences held a webinar on how to analyze multiple biomarkers using Immunohistochemistry (IHC). The session was a deep dive in the Tissue Microenvironment (TME) with multiplex IF (Opal™) technology, discovering how to visualize, analyze, and quantify multiple phenotypes in situ.

As part of a long-standing collaboration with Akoya Biosciences, we agreed to test our pre-validated 6-plex panel kits, including one suitable for carcinoma immune-contexture investigations (CD8, CD68, FoxP3, PD1, PD-L1, PanCK). We were also able to put into practice Akoya’s pre-set imaging protocol on the Vectra® Polaris™ and related data analysis algorithm with inForm® software.

Speakers

• Ivan Masetto, PhD, Field Application Scientist South of Europe at Akoya Biosciences
• Maroua Tliba, Image Analyst at Cerba Research

Despite the growing prevalence of NASH, there are currently no approved treatments for the disease beyond liver transplant. The constellation of risk factors for NASH has generated a multitude of targets and there is an obvious need to bring promising treatments through clinical trials and to patients quickly. 

In light of the global COVID-19 (SARS-Cov-2) pandemic, the search for a treatment or vaccine has become urgent and critical. Cerba Research, together with all its partners, is widely using COVID-19 diagnostic tests to detect the virus in patients. In addition, we are assisting in making testing available in clinical trials globally.

Please, feel free to reach out to us if our COVID-19 capabilities and overall understanding of coronavirus pathogenesis can help advance the development of your treatment.

Our Histoprofile®- T-reg light panel is ready for use in your clinical trials

Accurate characterization of the tumor micro-environment when tissue sample access is limited can be an important challenge in the field of immuno-oncology. The balance and tumor infiltration of T cell subpopulations are of particular interest and its importance has been repeatedly demonstrated in the literature. T cells are important immune effector cells and are therefore preferred targets for immuno-modulation.

Conventional T cells can be broadly classified as helper (Th), cytotoxic (Tcyto), memory or regulatory (Treg) cells. Tcyto cells ensure optimal immune responses against invading microbes and tumor antigens. Under homeostatic conditions, Tregs promote peripheral tolerance. However, within tumors, Tregs can supress Tcyto cell functions. The multiplex protocol, Histoprofile®- T-reg light panel, developed at Cerba Research on the Discovery ULTRA (Ventana) platform is designed to stain specific sub-populations of T cells on a single slide, avoiding the need of serial sections from precious patient’s FFPE samples in clinical trials while still providing an indepth analysis of the tumor microenvironment.

Our in-depth analytical validation ensures the quality of this robust protocol on solid tumor tissues. Evaluate T-cell subpopulations and their spatial distribution in the tumor microenvironment.